Send Message
View as an RSS Feed
  • PolyMet Mining: 3 Different Insiders Have Purchased Shares This Month  [View article]

    Last shareholder meeting:

    "The environmental review process is nearing completion, with permitting set to follow shortly after the Record of Decision on the final EIS,"
    Do you have any idea when it will be the final decision of EIS?...i saw some big buy blocks last 2 seems that a new strong movement could start soon

    Do have plans to update your SA article?
    Thanks in advance
    Jul 25, 2014. 08:02 PM | Likes Like |Link to Comment
  • Gevo Is On The Wrong Side Of The Fence  [View article]
    I think it is necessary a new seeking alpha article about this company to clarify some aspects.
    Dec 12, 2013. 01:49 PM | Likes Like |Link to Comment
  • Gevo Is On The Wrong Side Of The Fence  [View article]
    I share the same understanding about gevo business plan.

    The Isobutanol market is huge, and GEVO is very well positionated worlwide.

    Isobutanol is not ethanol.

    As growing company, Gevo in my opinion is a good investment going into 2014.

    And in 2014 

    Dec 12, 2013. 01:48 PM | 1 Like Like |Link to Comment
  • WidePoint: An Undervalued Provider Of Information Technology Solutions  [View article]
    Very well written!!

    What is your target with 600 Million dollar Dept of Homeland Security contract?

    Can you do an update on your article? And explain more about this contract.

    Thank you.
    Dec 10, 2013. 08:55 PM | 1 Like Like |Link to Comment
  • Venaxis Is Getting Ready To Take Off, All On Board?  [View article]
    Thank you for your article very useful.

    As someone wrote and i agree, the test will be used as part of protocol when a patient arrive to E.R.

    This is huge and at this stage the company has only a Market Value of 35Million.

    With positive and strong ph3 results APPY share Price could easily be at $3/4 that represents company value of 60/80 Million...and still very low cap. for the size of the APPY test.

    My opinion,
    Sep 8, 2013. 12:34 PM | 2 Likes Like |Link to Comment
  • Venaxis Is Getting Ready To Take Off, All On Board?  [View article]
    Excellent Article

    But just one more and very important catalysts for this month ( I think it is the most important before the final Ph3 results)

    More important than the conferences, wich is:

    - 2nd review from DSMB (Data and Safety Monitoring Board) with 1200 Patients . ( This should be adress to shareholders in the last week of Sep-13)

    The DSMB was created as part of the Company's pivotal clinical trial for the APPY1 Test and has the goal to recommend the continuation or not the study.
    Sep 8, 2013. 08:49 AM | 4 Likes Like |Link to Comment
  • Venaxis: The Hidden Gem With A 'Feel-Good' Investment Opportunity  [View article]
    Nice article. covering all major aspects.

    I would like to see a bit more about market size and how far can reach APPY in terms of revenues.

    Who knows. maybe in a next article.

    Aug 8, 2013. 04:08 PM | 1 Like Like |Link to Comment
  • Venaxis: Well-Funded Ahead Of Multiple Catalysts Expected Through Year-End  [View article]
    i see...

    But with strong ph 3 results, fda will approave the test.

    The alternative for the test could cause cancer between ages 2 to 20. And FDA are aware of that.
    Jul 31, 2013. 09:29 AM | 1 Like Like |Link to Comment
  • Venaxis: Well-Funded Ahead Of Multiple Catalysts Expected Through Year-End  [View article]
    What is your target with fda approaval? $6, $7?
    Jul 29, 2013. 09:50 PM | 1 Like Like |Link to Comment
  • Exclusive Interview With Stephen Lundy, Venaxis President And CEO  [View article]
    it will move 10%, 20% and more. Agree, there several candidates but i think appy is one of them. My opinion
    Jun 27, 2013. 05:09 PM | Likes Like |Link to Comment
  • Venaxis, Inc: A Long-Term Investment With Potential For Substantial Gains  [View article]
    APPY will do an update when enrollement equal to 600 and 1200.
    Jun 18, 2013. 03:29 PM | 1 Like Like |Link to Comment
  • Why You Should Be Investing In DNA Vaccination Technology And Inovio Pharmaceuticals  [View article]
    Very well written.
    May 16, 2013. 11:58 AM | 2 Likes Like |Link to Comment
  • Raptor Pharmaceutical (RPTP) says the FDA will require additional time to complete its review of the New Drug Application for RP103, Procysbi, for the potential treatment of nephropathic cystinosis. The company received notice today that the PDUFA goal date has been extended from January 30, 2013 to April 30, 2013in order to provide more time to complete the review of information submitted. The agency hasn't asked for any additional studies.  [View news story]
    3 Months more...well the most important is that RPTP has good chances of approaval. No more studies required...nice

    Will be interesting to see aproaval in EUA and in Europe almost at same time...

    Dec 21, 2012. 05:51 PM | Likes Like |Link to Comment
  • All Eyes on Alexza as Company Prepares to Re-File Drug Application  [View article]

    It seems that ALXA is trying to answer to all questions raised by the FDA and no major problems will appear.

    If they have good chances in EUA and Europe also, new parternships coming in, the truth is that the share price does not reflect all this potencial.

    Do think it is because the company is not known to many investors or are they simply waiting for Jully re-filling?

    May 25, 2011. 09:53 AM | Likes Like |Link to Comment
  • Biotech: Some CRL Recipients to Consider  [View article]
    Good afternoon.

    In your opinion, what should be the price target before the NDA resubmission in July and after in case of a positive opinion from FDA?

    Thank you
    May 16, 2011. 12:53 PM | Likes Like |Link to Comment